

143

1644/18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Examining Operations

Applicant(s): Bazin, et al.

Serial No: 09/056,072

Art Unit: 1644

Filed: April 7, 1998

Examiner: Gambel

Title: LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Activation and Proliferation

Attorney

Docket No.: 469201-701

TRANSMITTAL LETTER

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SIR:

Enclosed please find the following:

1. Response to Order to Show Cause;
2. Terminal Disclaimers;
3. Check in the amount of \$220.00; and
4. A self-addressed, postage paid, return receipt postcard, date stamp and return of which is respectfully requested.

The Commissioner is authorized to charge payment of any additional filing fees required under 37 C.F.R. 1.16 associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


*Raymond J. Lillie* 1/2/04  
Raymond J. Lillie, Esq. Date

Respectfully submitted,

*Raymond J. Lillie*  
Raymond J. Lillie, Esq.  
Reg. No. 31,778

CARELLA, BYRNE, BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
Five Becker Farm Road  
Roseland, New Jersey 07068  
T: (973) 994-1700  
F: (973) 994-1744

#206181 v1



# 23

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bazin, et al.  
Serial No. : 09/056,072  
Filed : April 7, 1998  
For : LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Activation and Proliferation  
Group : 1644  
Examiner : Gambel

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
JAN 20 2004  
TECH CENTER 1600/2900


RESPONSE TO ORDER TO SHOW CAUSE

Sir:


In response to the order to Show Cause mailed December 22, 2003, applicants submit herewith terminal disclaimers in order to obviate the obviousness-type double patenting rejections with respect to U.S. Patent Nos. 5,730,979 and 5,951,983.

Thus, Applicants, by filing the terminal disclaimers, have addressed the affirmed rejections that would have disposed of all claims. It is therefore respectfully requested that the Board consider the Request for Rehearing and Reconsideration filed on October 2, 2003 and that the outstanding rejections of Claims 30-32 and 35-37 under 35 U.S.C.102 (b) and of Claims 30-37 under 35 U.S.C.103 be reversed

Respectfully submitted,

  
Raymond J. Lillie  
Registration No. 31,778

#205941 v1



#24

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Bazin, et al.  
Serial No. : 09/056,072  
Filed: : April 7, 1998  
For : LO-CD2a Antibody and Uses Thereof for Inhibiting  
T-Cell Activation and Proliferation  
Group : 1644  
Examiner : Gambel

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED

JAN 20 2004

TECH CENTER 1600/2900

TERMINAL DISCLAIMER

Sir:

Université Catholique de Louvain, the assignee of the entire interest of the above-identified application, hereby disclaims the terminal portion of any patent granted on the above-identified application which is subsequent to the expiration date of U.S. Patent No. 5,951,983. Any patent granted on the above-identified Application shall be enforceable only for and during such period that said patent is commonly owned with U.S. Patent No. 5,951,983.

01/12/2004 YPOLITE1 00000122 09056072

01 FC:1814

110.00 OP

Respectfully submitted,

Raymond J. Lillie  
Registration No. 31,778